The Advanced Prostate Cancer Pipeline: A Continuum
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Drug development in advanced prostate cancer typically moves along a continuum, first targeting either castration-resistant (hormone-refractory) patients who have already taken the first-line chemotherapy docetaxel or the larger population of those who are chemotherapy-naïve after failing medical and surgical castration. Drugs that can reach into the hormone-sensitive prostate cancer population would reach even more patients. Below are selected drugs in late-stage development for advanced prostate cancer and their progress in the various indications.